ANTIBODY WHICH IS DIRECTED AGAINST GALECTIN-9 AND IS AN INHIBITOR OF THE SUPPRESSOR ACTIVITY OF REGULATORY T LYMPHOCYTES

• US 20170283499A1
• Filed: 06/05/2015
• Published: 10/05/2017
• Est. Priority Date: 06/06/2014
• Status: Active Grant

• Current Assignee: Cellvax Co., Centre National De La Recherche Scientifique, Institut Gustave Roussy, Université Paris-Saclay
• Original Assignee: Cellvax SA, Centre National De La Recherche Scientifique, Institut Gustave Roussy, Universite De Lille 2 Universite Du Droit Et De La Sante, Universite Paris - Sud, Universite Sciences Technologies LILL
• Inventors: Delhem, Nadira, Busson, Pierre, Morales, Olivier, Barjon, Clement, Mrizak, Dhafer, Lhuillier, Claire, Mustapha, Rami
• Granted Patent: US 10,899,838 B2
• Time in Patent Office: Days
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: C07K 16/2851 against the lectin superfamily, e.g. CD23, CD72
• CPC Class Codes: C07K 16/30 from tumour cells
• CPC Class Codes: C07K 16/3084 against tumour-associated gangliosides
• CPC Class Codes: C07K 16/3092 against tumour-associated mucins
• CPC Class Codes: C07K 2317/34 Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
• CPC Class Codes: C07K 2317/56 variable (Fv) region, i.e. VH and/or VL
• CPC Class Codes: C07K 2317/565 Complementarity determining region [CDR]
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

The invention relates to an antibody which is directed against galectin-9 and is an inhibitor of the suppressor activity of regulatory T lymphocytes, and also to the use of this antibody for the treatment of diseases associated with the suppressor activity of regulatory T lymphocytes, in particular the treatment of cancer.

Claims

1. An antibody directed against Galectin-9 and inhibiting the suppressor activity of regulatory T lymphocytes.

2. The antibody according to claim 1, which binds specifically to an epitope of an amino acid sequence SEQ ID NO:

9.

3. The antibody according to claim 1, having the same fixing zone as the antibody having as CDRs the six CDRs defined by:

the amino acid sequence SEQ ID NO;

2 in the region H-CDR1;

the amino acid sequence SEQ ID NO;

3 in the region H-CDR2;

the amino acid sequence SEQ ID NO;

4 in the region H-CDR3;

the amino acid sequence SEQ ID NO;

6 in the region L-CDR1;

the amino acid sequence SEQ ID NO;

7 in the region L-CDR2;

the amino acid sequence SEQ ID NO;

8 in the region L-CDR3.

4. The antibody according to claim 1, having as CDRs the six CDRs defined by:

the amino acid sequence SEQ ID NO;

2 in the region H-CDR1;

the amino acid sequence SEQ ID NO;

3 in the region H-CDR2;

the amino acid sequence SEQ ID NO;

4 in the region H-CDR3;

the amino acid sequence SEQ ID NO;

6 in the region L-CDR1;

the amino acid sequence SEQ ID NO;

7 in the region L-CDR2;

the amino acid sequence SEQ ID NO;

8 in the region L-CDR3.

5. The antibody according to claim 1, wherein the variable heavy-chain region of said antibody has the amino acid sequence SEQ ID NO:

1 and is that the variable light-chain region of said antibody has the amino acid sequence SEQ ID NO;

5.

6. The antibody according to claim 1, having the same fixing zone as the antibody having as CDRs the six CDRs defined by:

the amino acid sequence SEQ ID NO;

11 in the region H-CDR1.;

the amino acid sequence SEQ ID NO;

12 in the region H-CDR2;

the amino acid sequence SEQ ID NO;

13 in the region H-CDR3;

the amino acid sequence SEQ ID NO;

15 in the region L-CDR1;

the amino acid sequence SEQ ID NO;

16 in the region L-CDR2;

the amino acid sequence SEQ ID NO;

17 in the region L-CDR3.

7. The antibody according to claim 1, having as CDRs the six CDRs defined by:

the amino acid sequence SEQ ID NO;

11 In the region H-CDR1;

the amino acid sequence SEQ ID NO;

12 in the region H-CDR2;

the amino acid sequence SEQ ID NO;

13 in the region H-CDR3;

the amino acid sequence SEQ ID NO;

15 in the region L-CDR1;

the amino acid sequence SEQ ID NO;

16 in the region L-CDR2;

the amino acid sequence SEQ ID NO;

17 in the region L-CDR3;

8. The antibody according to claim 1, wherein the variable heavy-chain region of said antibody has the amino acid sequence SEQ ID NO:

10 and in that the variable light-chain region of said antibody has the amino acid sequence SEQ ID NO;

14.

13. A pharmaceutical composition, comprising the antibody according to claim 1 and at least one pharmaceutically acceptable carrier.

14. A combination product, comprising:

the antibody according to claim 1, and

an anticancer agent.

15. The combination product according to claim 14 for simultaneous use, separate use or use spread over time in the treatment of cancer.

16. The antibody according to claim 6, wherein the variable heavy-chain region of said antibody has the amino acid sequence SEQ ID NO:

10 and in that the variable light-chain region of said anti body has the amino acid sequence SEQ ID NO;

14.

17. The antibody according to claim 7, wherein the variable heavy-chain region of said antibody has the amino acid sequence SEQ ID NO:

10 and in that the variable light-chain region of said antibody has the amino acid sequence SEQ ID NO;

14.

18. A method of treating a cancer associated with the expression of Galectin-9 and with the suppressor activity of regulatory T lymphocytes, comprising the step of administering to a patient in need thereof a therapeutically active amount of the antibody according to claim 1.

19. The method of treating a cancer according to claim 18, wherein the cancer is chosen from the group consisting of chronic myeloid leukaemia, colon cancer, melanoma, cancer of the uterus, breast cancer, pancreatic cancer, gastric cancers, ovarian cancer, primary lymphoma of the central nervous system, multiple myelomas, prostate cancer, Hodgkin'"'"'s lymphoma or hepatocellular carcinoma.

20. The method of treating a cancer according to claim 18, wherein the cancer is a viro-induced cancer, preferably chosen from the group consisting of nasopharyngeal carcinomas associated with

9-12. -12. (canceled)